Literature DB >> 25425104

[Oncological diseases and postoperative alterations of the bladder and urinary tract].

M M Ong1, P Riffel, J Budjan, C Bolenz, S O Schönberg, S Haneder.   

Abstract

In the challenging evaluation of upper urinary tract malignancies multidetector computed tomography (CT) has become the standard imaging method. Cross sectional imaging not only allows the detection and visualization of the tumor itself but also provides nodal and metastasis staging in one examination (one-stop-shop). The majority of urothelial carcinomas are located in the urinary bladder. In this case, CT and more recently magnetic resonance imaging (MRI) can also deliver decisive information regarding TNM classification. A combination of clinical, histological, morphological and functional parameters allows both risk stratification and a targeted therapy based on the individual tumor stage.

Entities:  

Mesh:

Year:  2014        PMID: 25425104     DOI: 10.1007/s00117-014-2768-6

Source DB:  PubMed          Journal:  Radiologe        ISSN: 0033-832X            Impact factor:   0.635


  48 in total

1.  Gadolinium enhanced magnetic resonance urography for upper urinary tract malignancy.

Authors:  Naoki Takahashi; James F Glockner; Robert P Hartman; Bernard F King; Bradley C Leibovich; David W Stanley; Patrick D Fitz-Gibbon; Akira Kawashima
Journal:  J Urol       Date:  2010-02-19       Impact factor: 7.450

2.  What is the current role of CT urography and MR urography in the evaluation of the urinary tract?

Authors:  Stuart G Silverman; John R Leyendecker; E Stephen Amis
Journal:  Radiology       Date:  2009-02       Impact factor: 11.105

Review 3.  [Magnetic resonance urography in pediatric urology].

Authors:  D Schindele; C Furth; U B Liehr; M Porsch; D Baumunk; A Janitzky; J J Wendler; P Genseke; J Ricke; M Schostak
Journal:  Urologe A       Date:  2012-12       Impact factor: 0.639

4.  Diffusion-weighted MRI in bladder carcinoma: the differentiation between tumor recurrence and benign changes after resection.

Authors:  Huan-jun Wang; Margaret H Pui; Yan Guo; Dong Yang; Bi-tao Pan; Xu-hui Zhou
Journal:  Abdom Imaging       Date:  2014-02

5.  Apparent diffusion coefficient value reflects invasive and proliferative potential of bladder cancer.

Authors:  Shuichiro Kobayashi; Fumitaka Koga; Kohei Kajino; Soichiro Yoshita; Chikako Ishii; Hiroshi Tanaka; Kazutaka Saito; Hitoshi Masuda; Yasuhisa Fujii; Tetsuo Yamada; Kazunori Kihara
Journal:  J Magn Reson Imaging       Date:  2013-04-15       Impact factor: 4.813

6.  Evaluation of acute renal colic: a comparison of non-contrast CT versus 3-T non-contrast HASTE MR urography.

Authors:  M J Semins; Z Feng; B Trock; M Bohlman; W Hosek; B R Matlaga
Journal:  Urolithiasis       Date:  2012-12-25       Impact factor: 3.436

7.  Low-dose computed tomographic urography using adaptive iterative dose reduction 3-dimensional: comparison with routine-dose computed tomography with filtered back projection.

Authors:  Hiroshi Juri; Mitsuru Matsuki; Yuki Inada; Takahiro Tsuboyama; Seishi Kumano; Haruhito Azuma; Yoshifumi Narumi
Journal:  J Comput Assist Tomogr       Date:  2013 May-Jun       Impact factor: 1.826

8.  Utility of MRI features in differentiation of central renal cell carcinoma and renal pelvic urothelial carcinoma.

Authors:  Natasha E Wehrli; Min Ju Kim; Brent W Matza; Jonathan Melamed; Samir S Taneja; Andrew B Rosenkrantz
Journal:  AJR Am J Roentgenol       Date:  2013-12       Impact factor: 3.959

9.  EAU guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2013 guidelines.

Authors:  J Alfred Witjes; Eva Compérat; Nigel C Cowan; Maria De Santis; Georgios Gakis; Thierry Lebret; Maria J Ribal; Antoine G Van der Heijden; Amir Sherif
Journal:  Eur Urol       Date:  2013-12-12       Impact factor: 20.096

10.  Assessing renal function in children with hydronephrosis - additional feature of MR urography.

Authors:  George Hadjidekov; Savina Hadjidekova; Zahari Tonchev; Rumiana Bakalova; Ichio Aoki
Journal:  Radiol Oncol       Date:  2011-11-16       Impact factor: 2.991

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.